Version history

11 versions on record. Newest first; the live version sits at the top with a live indicator.

  1. Live
    4/27/2026, 2:59:17 PM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "world_model_rank": 0,
  "kg_impact_score": 0,
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html",
  "reproducibility_class": "observational"
}
  2. v10
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  3. v9
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  4. v8
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  5. v7
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  6. v6
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  7. v5
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  8. v4
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  9. v3
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  10. v2
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}
  11. v1
    4/2/2026, 6:36:48 AM
    Content snapshot 
    {
  "question": "Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for treating neurodegenerative diseases including Alzheimer disease, Parkinson disease, Huntington disease, and ALS. Consider approaches targeting causal mutations (e.g., HTT CAG repeats, SOD1, APP), epigenetic modulation (CRISPRa/CRISPRi), base editing, prime editing, and in vivo delivery challenges (AAV, lipid nanoparticles, blood-brain barrier penetration). Assess current preclinical evidence, ongoing clinical trials, and key hurdles for clinical translation.",
  "domain": "neurodegeneration",
  "status": "archived",
  "triggered_by": "autonomous",
  "gap_id": "gap-crispr-neurodegeneration-20260402",
  "report_url": "/analyses/sda-2026-04-02-gap-crispr-neurodegeneration-20260402.html"
}